A Roadmap for the Development of Ivermectin as a Complementary Malaria Vector Control Tool. by The Ivermectin Roadmappers et al.
Am. J. Trop. Med. Hyg., 102(Suppl 2), 2020, pp. 3–24
doi:10.4269/ajtmh.19-0620
Copyright © 2020 by The American Society of Tropical Medicine and Hygiene
A Roadmap for the Development of Ivermectin as a Complementary Malaria Vector Control Tool
The Ivermectin Roadmappers1*
1Full List of Contributors in the Acknowledgments
Abstract. In the context of stalling progress against malaria, resistance of mosquitoes to insecticides, and residual
transmission,mass drug administration (MDA) of ivermectin, an endectocide used for neglected tropical diseases (NTDs),
has emerged as a promising complementary vector control method. Ivermectin reduces the life span of Anopheles
mosquitoes that feed on treated humans and/or livestock, potentially decreasing malaria parasite transmission when
administered at the community level. Following the publication by WHO of the preferred product characteristics for
endectocides as vector control tools, this roadmap provides a comprehensive view of processes needed to make
ivermectin available as a vector control tool by 2024 with a completely novel mechanism of action. The roadmap covers
various aspects, which include 1) the definition of optimal dosage/regimens for ivermectin MDA in both humans and
livestock, 2) the risk of resistance to the drug and environmental impact, 3) ethical issues, 4) political and community
engagement, 5) translation of evidence into policy, and 6) operational aspects of large-scale deployment of the drug, all in
the context of a drug given as a prevention tool acting at the community level. The roadmap reflects the insights of a
multidisciplinary group of global health experts whoworked together to elucidate the path to inclusion of ivermectin in the
toolbox against malaria, to address residual transmission, counteract insecticide resistance, and contribute to the end of
this deadly disease.
INTRODUCTION
Malaria situation.Malaria remainsa significantpublichealth
problemworldwide,particularlyacross low-andmiddle-income
regions. Although thedisease isbothpreventable andcurable,
it currently threatens nearly half of theworld’spopulation living
in 90 malaria-endemic countries.1 Over the last two decades,
the large-scale implementation of preventive strategies, as
well as the improvements in the diagnosis and treatment of
the disease, has led to an 18% global drop in incidence rates
between 2010 and 2017.1 Vector control with insecticide-
treated nets (ITNs) and indoor residual spraying (IRS) is con-
sidered the main driver of these malaria gains (i.e., ITNs and
IRS accounted for 78% of the malaria cases averted between
2000 and 2015).2 Despite these advances, in 2017, there were
219 million cases and 435,000 malaria deaths estimated
globally, with 93% of deaths occurring in Africa.1 After over a
decade of downward trends, the 2017 and 2018Worldmalaria
reports have shown that progress has stalled, especially in
high-burden countries. This poses a great challenge in achiev-
ing the morbidity and mortality targets of the WHO Global
Technical Strategy (GTS) for Malaria 2016–2030.1,3
Among the challenges currently weakening vector control
are mosquito resistance to insecticides and residual trans-
mission. Residual transmission is defined as the persistence
of malaria transmission after universal coverage with effective
ITNs and/or IRS to which the local vectors are fully suscepti-
ble.4 Through behavioral adaptations, mosquitoes are able to
avoid the standard vector control measurements by biting
while humans are not protected by ITNs and/or outdoor, as
well as feedingonperi-domestic livestock. Thus, research and
product development are critical to mitigate the existing pro-
tection gaps. Along these lines, the GTS5 and the research
agenda for malaria control proposed by the malERA consul-
tativegroup6 reflect theneed for improved ITNsand innovative
ways of controlling residual transmission.
The potential role of ivermectin as a complementary
vector control tool against malaria. Ivermectin is a long-
established veterinary endectocide, first approved for human
use for its antiparasitic activity against onchocerciasis in
1987.7 In 2018, global health authorities celebrated 30 years
of ivermectin mass drug administration (MDA) campaigns
against two neglected tropical diseases (NTDs), onchocerci-
asis, and lymphatic filariasis (LF).8 Besides its broad antipar-
asitic activity, ivermectin can kill mosquitoes that feed on
treated humans and livestock during a dose-dependent
period.9–12 This occurs because ivermectin binds selectively
to the glutamate-gated chlorine channel of invertebrates and
produces paralysis.7 By exploiting this mosquitocidal activity,
ivermectin MDA to humans and/or livestock could comple-
ment the malaria toolbox, reducing mosquito survival re-
gardless of their biting patterns.
The notion of repurposing ivermectin for malaria control
originally emerged in 1985 when in vitro tests showed that the
drug killed the malaria vector Anopheles stephensi.13 Addi-
tional data appeared slowly thereafter. A study in Papua New
Guinea in 1999 demonstrated that even a single-standard
dose of ivermectin affected vector survival in the field.14 A
randomized controlled trial further supported the killing ef-
fect on mosquitoes feeding on treated people.15,16 More re-
cently, the results of several modeling, pharmacological, and
insectary-based research studies, as well as several clinical
and field MDA trials, have positioned ivermectin as a first-in-
class tool to enhance malaria control.17–19
After recognizing the potential for endectocides to tackle
the issue of residual transmission, the WHO held a technical
consultation on ivermectin in 2016. Subsequently, preferred
product characteristics (PPCs) for endectocides against
malaria were published with ivermectin as a reference prod-
uct.20 The meeting report, endorsed by the Malaria Policy
Advisory Committee (MPAC), also established the require-
ment for a WHO policy recommendation on ivermectin for
malaria control. This requirement is that a minimum 20% de-
crease in malaria incidence should be achieved for at least
1month posttreatment after a single round of ivermectin MDA
when added to the standard vector control tools.20 Given this
* Address correspondence toCarlosChaccour, Barcelona Institute for
GlobalHealth (ISGlobal), Rosello132,Barcelona08036,Spain.E-mail:
carlos.chaccour@isglobal.org
3
momentum, several fundersbegansupporting theevaluationof
endectocides against malaria, reflecting the new guidance and
broad interest in this innovative approach (current and planned
trials are discussed in section Ongoing/planned trials).
The malaria Ivermectin Roadmap. The objective of the
Ivermectin Roadmap is to define a clear pathway for the eval-
uation of ivermectin as a vector control tool againstmalaria and
for its subsequent implementation. Specifically, this analysis
has carefully considered: 1) product development (e.g., dose
and regimen), 2) evidence to support a global policy recom-
mendation (e.g., safety and efficacy), and 3) access and de-
ployment at scale (e.g., procurement and delivery mode).
Throughout the different sections of this article, key research
and development (R&D) questions havebeen identified so as to
outline anR andD agenda for the development of ivermectin as
a complementary vector control tool.
Over the past 4 years, experts in relevant fields have defined
the critical aspects of repurposing ivermectin as a comple-
ment to current malaria vector control tools. In 2014, the
Ivermectin Research forMalaria EliminationNetwork,21 began
shaping the concept. The Ivermectin Roadmappers were as-
sembled in 2017 after funding was granted by the Bill &
Melinda Gates Foundation. A launch meeting took place at
the 2017 Annual Meeting of the American Society of Tropical
Medicine and Hygiene (ASTMH) in Baltimore (US). The multi-
disciplinary team included global health experts whose
backgrounds encompassedentomology, infectiousdiseases,
vaccines, veterinary, environmental sciences, ethics, financ-
ing systems, clinical trials, supply chain management, and
scaling-up of interventions, among others (see full list of
contributors on pages 18–19).
The process to develop this roadmap consisted of literature
reviews by the participants, as well as discussions with reg-
ulatory agencies, policy and funding bodies, drug manufac-
turers, and future implementing partners, including the WHO
and Unitaid. A synthesis meeting was held in Sitges (Spain) in
May 2018, where key aspects were discussed and refined.
The outcomes of the gatheringwere publicly presented during
the symposium “A Roadmap for Ivermectin as a Comple-
mentary Vector Control Tool for Malaria” at the 2018 ASTMH
AnnualMeeting (https://mesamalaria.org/resource-hub/astmh-
2018-session-30-roadmap-ivermectin-complementary-vector-
control-tool-malaria) and are now reflected in this roadmap.
THE GOAL
Vision. To accelerate global malaria control and elimi-
nation with a novel vector control tool that addresses re-
sidual transmission and mitigates the risk of insecticide
resistance.
Strategic goal. To advance a complementary strategy for
vector control that reduces malaria burden (incidence) by at
least 20%whendeployedat the community level in addition to
ITNs and/or IRS.
PRODUCT DEVELOPMENT NEEDED TO REPURPOSE
IVERMECTIN TO MALARIA
Use scenarios. The rationale for an ivermectin-based ap-
proach against malaria is that it reduces the longevity of
mosquitoes that feed on ivermectin-treated subjects. The ef-
fect is dose-dependent. Thus, deploying ivermectin to an
important (or significant) proportion of humans and/or the
predominant herd during the malaria season could signifi-
cantly reduce transmission of the disease. Moreover, the
resulting decline in mosquito populations can boost the ef-
fects of core vector control tools (i.e., ITNs or IRS), leading to
anoverall higher impact. Thecommunity delivery of ivermectin
has the potential to fill an important gap in vector control by
addressing residual transmission. Residual transmission is
driven by mosquitoes biting outdoors and/or early in the
evening, mosquitoes feeding on peri-domestic livestock, and
human behaviors that decrease the effectiveness of current
vector control programs. In addition to tackling residual
transmission, ivermectin belongs to a different chemical class
than the active ingredients present in ITNs or sprays, poten-
tially contributing to insecticide resistance management.
Such properties place ivermectin MDA as an attractive addi-
tion to the malaria control toolbox. Other MDA strategies with
blood and/or tissue schizonticidal drugs address the parasite
biomass circulating in the human population and do not im-
pact the vector or the parasites they may be carrying. How-
ever, before deployment, key questions regarding the delivery
of this drug will need to be answered, including the determi-
nation of the range of effective and safe doses, the target
population, the required level of community uptake, the
malaria epidemiologic context, and the distribution strategies,
among others.
Given the considerable effort associated with the high-level
community delivery of a relatively short-acting drug, the use of
ivermectin could be suitable for short and intense use, as
opposed to the more enduring use of other measures such
as ITNs.20 There are different potential approaches to the
implementation of ivermectin MDA as vector control:
1. Ivermectin alone to complement the national strategy of
deploying ITNs and IRS.
2. Ivermectin MDA combined with antimalarial drugs to simul-
taneously clear infections in humans, provide time-limited
chemoprevention, and prevent transmission, increasing
impact.
3. Ivermectin co-administered at the same time as seasonal
malaria chemoprevention (SMC) programs in areas with a
short transmission season. Although the target populations
of SMC and ivermectin MDA differ, the latter could benefit
from the current door-to-door delivery strategy of SMC to
children in households, to also deliver ivermectin to the rest
of the eligible population.
4. In parallel, in many but not all areas where malaria ivermectin
MDA would be distributed, there may exist the opportunity to
create synergies with the national NTD treatment programs
because twice a year, ivermectin is often recommended for
onchocerciasis and for LF eradication. The need to deliver as
part of a combination regimen for LF, varying dosages across
programs, and different sources of ivermectin need to be ra-
tionalized where joint programming is considered.
Taking the aforementioned key aspects into account,
Table 1 summarizes potential use scenarios for ivermectin as
vector control. Notably, the first four scenarioswill be tested in
various trials through 2023.
Target population. Ivermectin MDA is a vector control in-
tervention designed to be administered to humans to affect
the survival of mosquitoes that feed on them. In addition, farm
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animal ownership has been described as a risk factor for hu-
manmalaria infection in areaswheremosquitoes feed on both
animals and humans; thus, the administration of ivermectin to
both sources of blood has been proposed.22–25 Conveniently,
ivermectin is an antiparasitic drug already broadly used in
human and veterinary contexts to treat a range of endo- and
ectoparasites.26 Ivermectin MDA would target mosquitoes
feeding on treated subjects (humans or animals) regardless of
their biting patterns. A key concept is coverage threshold for
efficacy based on the target population. In human pop-
ulations, modeling suggests that coverage as low as 60%
could have a significant impact on transmission,27,28 but no
model has yet explored the impact threshold for targeting
livestock and humans together. Although the advantages and
impact of treating humans only, livestock only, or both need to
be assessed in field studies, covering the two sources of
mosquitomeals could result inmajor impact on human health,
especially in settings where the principal malaria vector spe-
cies exploit both as sources of blood meals.
Malaria endemicity. The introduction of ivermectin to sup-
press vectorial capacity could be beneficial in a range of
malaria transmission intensities. This report considered the
value of ivermectin as a complementary tool to achieve impact
in high-transmission areas, as well as serving as a short-term
adjunct to achieving elimination in lower incidence areas. In
such settings, ivermectin MDA would indirectly target the
mosquitoes, in contrast to MDA with antimalarials in which
the aim is to decreasemalaria burden by directly attacking the
human reservoir for the parasite. However, the combination of
ivermectin MDA for vector effect and antimalarials for parasite
effect has been proposed in various scenarios.
Efficacy. The efficacy of ivermectin against malaria arises
mainly from the mosquito-killing capacity of the drug when
ingested during a blood meal. Additional sublethal effects
that could affect the mosquito and/or the parasite in the
mosquito and, therefore,malaria transmission, have alsobeen
described.29,30 Mosquitoes fed with ivermectin-containing
blood have shown negative alterations on their fertility and
flying ability.29,30 Likewise, the development of blood and
liver-stage parasites has been inhibited by ivermectin in vitro
and mouse models.31,32 However, the magnitude and mech-
anism of this effect in humans has yet to be fully studied.
Because sublethal outcomes will require further elucidation,
this report focuses exclusively on mosquito mortality as the
primary determinant of ivermectin efficacy.
The lethality of ivermectin is a function of three key param-
eters: 1) concentration: drug blood levels reached, 2) time: the
duration of the drug circulating at effective concentrations in
TABLE 1
Potential use scenarios for ivermectin in different transmission settings, delivered to different target blood sources, and under several co-delivery
models
Transmission
setting
Rationale for ivermectin
use Target blood source Always present Additional co-delivery Rationale for co-delivery
Higher Reduce disease
burden
Human Asper national policy:
ITNs or IRS Case
management IPTp
SMC UsingSMCasaplatform for
ivermectin delivery,
operational synergism is
achieved
Higher Accelerate to
elimination
Human ACT MDA Ivermectin provides
additional transmission
reduction by targeting
outdoor and early biting
vectors
Higher Reduce vectorial
capacity
Livestock Behavior change
interventions to boost
ITN use and treatment
of cases
Protect households and
drive vectors to
zoophagy; this strategy
allows the use of long-
lasting veterinary
formulations
Higher Reduce vectorial
capacity
Human + livestock With or without ACT MDA Covering different blood
sources could increase
impact on local vector
populations
Higher Reduce vectorial
capacity
Human IRS timed after ivermectin
MDA
Improve IRS efficacy by
precipitating a sharp
reduction in vectors right
before the IRS campaign
Any Reduce disease
burden Reduce
vectorial capacity
Human NTD interventions such as
azithromycin or IDA for
lymphatic filariasis
As part of joint efforts with
NTD programs
Any Insecticide
resistance
management
Human ± livestock PBO and next-generation
nets, other insecticide
delivery vehicles, i.e.,
attractive targeted sugar
baits
As part of an insecticide
resistance management
strategy
Lower As part of reactive
interventions
Human ± livestock As part of focal MDA with
ACT ± other vector
control tools
Prevention of secondary
cases at low
transmission levels
Any Prevent or manage
outbreaks
Human ± livestock MDAwithACT+ ivermectin ±
other vector control tools
As a way to quickly reduce
vectorial capacity
IDA = triple therapy with ivermectin, diethylcarbamazine and albendazole; IPTp = intermittent preventive treatment in pregnancy; IRS = indoor residual spraying; ITN = insecticide-treated net; MDA =
mass drug administration; NTD = neglected tropical disease; SMC = seasonal malaria chemoprevention
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blood, and 3) coverage: the proportion of blood sources
covered (Figure 1). In other words, the mosquito-killing effect
is intrinsically related to the ivermectin concentration reached
in the subject (human or animal), the time this concentration is
sustained in the blood, and the number of subjects reached.
Concentration. The commonmetric for ivermectin lethality is
the lethal concentration 50 (LC50), which is defined as the
concentration needed to kill 50% of the biting mosquitoes
during a specific period of observation.17 Although the use of
LC50 values are accepted by the scientific community, studies
to assess the susceptibility ofmosquitoes to ivermectin are not
standardized, posing a challenge to deriving definite conclu-
sions. For instance, LC50 data are often presented in a variety of
time intervals, such as 24 hours, 5 days, 7 days, or 9 days, as
shown in Table 2. Besides the disparity in time frame, the
feeding methods for the LC50 assay also differ, potentially
influencing the outcome (i.e., mosquitoes fed in vivo through a
direct skin blood meal or in vitro via a membrane-feeding de-
vice). Moreover, in vitro experiments can be performed in
two ways, using ivermectin-spiked blood or using blood from
ivermectin-treated vertebrates. Last, blood meals may come
from human or animal blood treated with ivermectin only, or in
combination with antimalarials, adding extra variability.
Equally challenging is the great variation of the LC50 between
Anopheles species (Table 2). In general, the mosquito vulnera-
bility in a specific region will be partly defined by the least sus-
ceptible species being targeted (provided said species has a
relevant role in transmission), which is considered as the dose-
defining species and can vary somewhat across geographical
areas. The main implication of this finding is that characteriz-
ing the major vectors in a geographic area and validating sus-
ceptibility test results from colony mosquitoes with those of
wild-type mosquitoes will be a prerequisite to determine the
dose-defining species and to implement ivermectin for vector
control. Note that the time from feeding to mosquito death is
dose-dependent (i.e., dependent on the ivermectin concentra-
tion in the blood at the time of biting) with higher doses short-
ening survival to a few hours, but even mosquitoes exposed to
concentrations below 1 ng/mL still experienced reduced 28-
day survival,33 which can contribute to reduce transmission.
The total mosquito mortality achieved in the system with any
given dose/regimen will depend on the area under the curve of
the drug’s PK and the population coverage achieved.
Time.Modeling predicts that themain driver on transmission
reduction with ivermectin MDA is the duration of the drug
concentration abovemosquito-killing levels in the blood.28 The
longer the ivermectin is available in the blood of treated sub-
jects, the greater the impact on mosquito survival or fitness.
Thus, the short-lasting presence of ivermectin represents an
important challenge to be overcome through innovative ap-
proaches to enhance the duration of effect of ivermectin or
through alternative active ingredients to be developed.
Dosing and regimen considerations. The dose and regimen
for ivermectin delivery must be designed to optimize im-
pact while ensuring maximum safety. These are key factors
that impact on the concentration and duration of ivermectin
in blood and, therefore, the efficacy of the intervention. Ide-
ally, mosquito-lethal concentrations of ivermectin would be
FIGURE 1. The theoretical efficacyof ivermectinmassdrugadministrationbasedon three keyparameters: (A) blood levels reached, (B) durationof
blood levels, and (C) blood sources covered. This is a modified version of an original figure in by Chaccour and Rabinovich.19
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sustained in the blood for as long as possible, while avoiding
human toxicity andminimizing the number ofMDAcampaigns
required. Ivermectin’s toxicity in humans is the result of cross-
binding toGABA-gated channelswhich are only present in the
central nervous system (CNS) and, hence, protected by the
blood brain barrier (BBB). So, ivermectin toxicity in mammals
is related to its level in the CNS, which is not necessarily re-
lated to theblood levels but to the integrity/maturity of theBBB
and the activity of BBB-related efflux pumps such as the
P-glycoprotein.34
The ivermectin label has been modified extensively over 30
years of treatment and prevention of NTDs. The current Fed-
eral Drug Administration (FDA)–approved ivermectin dose for
onchocerciasisMDA is a single dose of 150–200 μg/kg yearly,
although the possibility of quarterly use in individual patients is
also included on the label for areas with high onchocerciasis
transmission.35 Formoderate to severe crusted scabies, three
doses of 200 μg/kg within 2 weeks are recommended in the
Stromectrol® Australian label.26 Of relevance, the 400 μg/kg
single dose yearly MDA is included on the Mectizan® and
the Stromectrol labels, both approved by the European Medi-
cines Agency (EMA).36
Currently, two potential regimens are being considered
for malaria clinical trials (see section Assessment of expected
impact). One is the single 400 μg/kg dose that is in the
EMA-approved ivermectin label, repeated three times during
the malaria season. The second is a three-dose regimen of
300 μg/kg taken on 3 consecutive days (days 1–3), in combi-
nation with the artemisinin-based combination therapy (ACT),
dihydroartemisinin–piperaquine, in three rounds administered
during themalaria season.37 During the roadmapdevelopment,
a modeling exercise was performed to evaluate the impact
of both options in different transmission scenarios (Slater,
unpublished). Figure 2 displays an example of a three-round
deployment of ivermectin 1 month apart, each right at the start
of the rainy season, at either the 1 × 400 or the 3 × 300 dose in a
perennial transmission setting in northern Mozambique. The
effect of the intervention is shown as the variation of clinical
incidence of malaria over time for both all-age and under-five
populations. The model shows that three doses of 300 μg/kg,
used monthly for 3 months, could reduce clinical infection in-
cidence by 50%, whereas a single dose of 400 μg/kg would
reduce it by about 40%. Notably, although the difference be-
tween the two regimens is potentially measurable at the pop-
ulation level, other factors to be taken into account are the
delivery logistics, cost-effectiveness, and community accept-
ability of each option. In the 3 × 300 regimen, the first dose is
directly observed, whereas the remaining two doses are un-
observed. Although this model was successfully used in SMC
programs,38 it could lead to adherence concerns, particularly
over time. There is a risk that the concurrent useof a single dose
for NTDs and multiple-dose regimens for malaria may create
confusion and affect acceptability by the community. Alterna-
tively, the successful delivery of a single higher dose of 400 μg/
kg may achieve greater effectiveness at the community level
without a significant trade-off in efficacy. A thorough compari-
son of the two approaches is shown in Table 3.
Ivermectin dose is currently administered to humans during
MDA campaigns using height as a proxy for weight with a
validated dosing pole. Regardless of the final dosage for
vector control, the development of a single dose for adults
would facilitate operations and, most importantly, allow for
easier co-administration, co-packaging,orevenco-formulation
with companion drugs for either NTDs or for malaria indication.
In addition, height to weight ratios may need to be revalidated
for higher doses.39
TABLE 2
Susceptibility to ivermectin in a blood meal of key malaria vectors, ordered by species
Reference Species Method Susceptibility
Gardner et al.101 An. quadrimaculatus Feeding on treated dogs 24-hour-LC50: 6–12 ng/mL
Ouedraogo102 An. gambiae Membrane: blood from treated humans in
combination with
artemether–lumefantrine
7-day-LC50: 8.6 ng/mL
Smit et al.37 An. gambiae Membrane: blood from treated humans in
combination with
dihydroartemisinin–piperaquine
7-day-LC50: 3.4 ng/mL
Kobylinski et al.103 An. gambiae (G3 strain) Membrane: in vitro mixture (human
blood + ivermectin)
5-day-LC50: 22.4 ng/mL
Kobylinski104 An. gambiae (G3 strain) 7-day-LC50: 15.9 ng/mL
Fritz et al.12 An. gambiae s.l. Membrane: in vitro mixture (cattle
blood + ivermectin)
9-day-LC50: 19.8 ng/mL
Kobylinski et al.105 An. dirus Membrane: in vitro mixture (human
blood + ivermectin)
7 day-LC50: 55.6 ng/mL
An. minimus 7 day-LC50: 16.3 ng/mL
An. campestris 7 day-LC50: 26.4 ng/mL
An. sawadwongporni 7 day-LC50: 27.1 ng/mL
Kobylinski [unpublished] An. dirus Membrane: blood from treated humans 10-day-LC50: 2.9 ng/mL
Kobylinski [unpublished] An. minimus 10-day-LC50: 0.4 ng/mL
Sampaio et al.106 An. aquasalis Membrane: in vitro mixture (blood +
ivermectin)
5-day-LC50: 47.03 ng/mL
Kobylinski et al.107 An. darlingi Membrane: in vitro mixture (blood +
ivermectin)
7 day-LC50: 43.2 ng/mL
Chaccour et al.22 An. arabiensis Feeding on treated cattle 10-day-LC50: 3.7 ng/mL
Fritz23 An. arabiensis (Dongola strain) Membrane: in vitro mixture (cattle
blood + ivermectin)
9-day-LC50: 7.9 ng/mL
Pasay108 An. farauti Feeding on treated pigs 12-day-LC99: 2.4 ng/mL*
An. =Anopheles. In vitro and in vivo data for humans and/or animals are presented. Note the variability in LC50 valueswhen using ivermectin-spiked blood or blood from treated vertebrates. In all
cases, in vivo data produce a stronger lethal effect when calculating LC50s. LC50 not available. Results by Dreyer et al.
109 showing an in vitro LC50 of 1,468 ng/mL for An. albimanus have been
published, so they are included here for completeness but there are new, unpublished field data by the same team showing LC50 of 34 ng/mL or lower.
* Only LC99 available.
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Because the efficacy of ivermectin is limited by the short-
lived effect of the drug, long-lasting formulations of ivermectin
or novel compounds with longer duration would represent an
important improvement. Already, slow release formulations of
ivermectin are currently under study showing positive pre-
liminary data on efficacy and safety of implants,22,40,41 but
scalability of implants could be challenging. There are other
formulations such as patches or innovative gastric retention
devices,27 which require further product development for
safety as well as efficacy. Alternatively, a new class of mole-
cules from the veterinary market known as isoxazolines has
shown a better pharmacokinetic profile. When tested against
malaria vectors, the predicted insecticidal activity of iso-
xazolines was 50–90 days.42 However, these molecules have
received a U.S. FDA veterinary safety warning about potential
for neurologic adverse events in dogs, and thus, further de-
velopment for administration to humans for malaria impact is
uncertain.43
Coverage. The third driver of efficacy is coverage, which is
theproportionof eligible blood sources treated. In areaswhere
mosquitoes feed on both humans and animals, and livestock
are targeted, coverage of livestock enters as a variable of
coverage.44 In humans, the determinants of coverage are
acceptance of the intervention, drug safety (through the scope
of target population), and adherence. As in other public health
interventions, outside of a clinical trial, good acceptance will
require evidence of impact, aligned with strong community
mobilization and engagement. In animals because it is a li-
censed product with benefits to health and productivity of
herds, determinants of coverageasveterinaryMDA formalaria
include access, supply, and delivery chain at a timing to par-
allel human administration and the malaria season.
Ivermectin provides personal benefits against NTDs and
ectoparasites, but it represents a novel paradigm of vector
control for malaria, in which the benefit to the community is
indirect, rather than directly to the individuals. Therefore, the
concept of community impact needs to bewell understood by
the community and by the global and national policy-makers.
The fact that ivermectin has proven to be a safe drug for
almost 30 years facilitates the pathway toward its repurposing
FIGURE 2. Modeled impact of the intervention across one transmission season in northern Mozambique. On the left, general population; on the
right, children younger than five years (analysis by Hannah Slater).
TABLE 3
Advantages and disadvantages of the two ivermectin regimens for malaria being tested in clinical trials through 2023
Advantages Disadvantages
3 × 300 μg/kg daily doses per month
“3 × 300”
Longer effect and, therefore, higher
efficacy
Lower coverage expected (as evidenced
in malaria community has experience
with SMC and MDA 3-dose regimens)
May have longer regulatory pathway,
requiring additional safety andpediatric
data for approval of a new dose and
regimen
1 × 400 μg/kg dose per month “1 × 400” Expected increased uptake and
scalability with a single dose
Shorter duration of effect and, therefore,
potentially lower impact
Dose already approved under European
Medicines Agency, in France and the
Netherlands for LF MDA, may facilitate
the regulatory process
Dose is used only in a few countries with
LF
Simpler to consider under national
program guidelines and potential for
synergies with NTD programs
Similarity to NTD programs could
enhance community acceptance.
LF = lymphatic filariasis; MDA = mass drug administration; NTD = neglected tropical disease.
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formalaria use.However, higher ormore frequent dosesmight
be required for this new function, and thus, its safety profile
may need to be re-evaluated to facilitate WHO evaluation.
Last, acceptability and coverage might be negatively affected
by low adherence if multiple-dose regimens are used. The
shortest course of treatment could simultaneously ensure
significant decrease in malaria transmission as well as pro-
grammatic feasibility and compliance.
Research and development agenda.
1. Definition of minimum mosquito data and stratification cri-
teria for ivermectin implementation at scale.
2. Once efficacy is determined, validation of dosing pole for
older children to simplify delivery. Dose-ranging studies
and development of a single pill for adults that does not
require weight adjustment would simplify operations.
3. Cross-study analysis of the impact in the field of 3 × 300
versus 1 × 400 of ongoing trials. Trade-offs between effi-
cacy, programmatic feasibility and coverage, and com-
munity acceptancewould be useful to guide efficient phase
four studies of scale-up.
4. Development of improved formulations of ivermectin or
other endectocides with acceptable safety profile and
prolongedmosquito-killing time (e.g., slow release, patches,
and new AIs).
Proven epidemiological impact. As of May 2019, the only
field clinical trial that demonstrated the impact of ivermectin
MDAonmalaria transmissionwasRIMDAMAL.45 This cluster-
randomized trial evaluated efficacy against clinical malaria
incidence in Burkina Faso after six ivermectin MDA delivered
as single doses (200 μg/kg) every 3weeks. A 20% reduction in
malaria incidence in children £ 5 years old was shown with a
community coverage of approximately 70%. The statistical
significance of these findings has been the subject of
debate.46,47 There are five ongoing or proposed trials with the
two leading drug doses and regimens, in three rounds of drug
administration (see section Ongoing/planned trials). More-
over, there are a number of other ivermectin trials of varying
dose and regimen for NTD applications (see MESA Track
https://mesamalaria.org/mesa-track).
Safety. Safety of different dosage and regimens. Ivermectin
has been used for more than 30 years with an excellent safety
profile. More than 2.7 billion doses have been distributed
both as individual treatment and as control of NTDs at the
approved dose of 150–200 μg/kg, yearly, and with no major
safety concerns.48 These programs are implemented in areas
nonendemic for Loa loa, use a validated dosing pole to deliver
to children > 15 kg, with a defined dose/kg, and do not ad-
minister the drug to pregnant women.
However, to attain the desired mosquito-killing effect for
malaria applications, higher doses/more frequent regimens
will be required. Given that the benefit of the community-
based delivery of ivermectin for malaria is indirect, both the
safety profile of the repurposed regimen and the risk-benefit
analysis will be key for the success of this intervention.
Two dosing regimens are currently planned for evaluation in
different trials. The safety of the proposed 400 μg/kg single-
dose (1 × 400) scheme has been well established in clinical
studies, as more than 60,000 thousand independent drug
exposures have occurred in clinical trials (Supplemental
Annex 1). No reported serious drug-related adverse events
and only minor adverse events related to immune reactions
fromparasitedeathandclearancewereobserved (e.g., itchiness,
myalgia, headache), with these disappearing within 1 week.
The safety profile of the second scheme proposed, a single
daily dose of 300 μg/kg for 3 days (3 × 300), has been initially
established in a single trial,37 and thus, it will require com-
prehensive safety assessment in larger clinical trials regard-
less of target disease. The key pharmacokinetic profiles of the
proposed malaria regimens and those of other currently ap-
proved regimens are shown in Table 4.
Exclusion criteria and drug interactions. Existing exclusion
criteria for administration of ivermectin against NTDs include co-
infection with L. loa (> 30,000mf/mL), pregnant women, children
under 15 kg (or 90 cm as proxy), andwomen nursing babies that
are younger than 1 week. This is because there is preclinical
evidenceofmaternal and/or fetal toxicityat veryhighdoses (10 to
150-fold) of ivermectin in pregnant mammals. A few clinical
studies have evaluated the effects of inadvertent treatment dur-
ing pregnancy without observed negative effects on either the
mother or the newborn.49–54 A systematic review of the safety of
ivermectin in inadvertently exposed mothers is in press (P. Nic-
olas, personal communication), and this can be supplemented
with similar cases from active trials, but there is yet no stan-
dardized database of pregnancy exposures.
Although preclinical data in young monkeys show no ad-
verse effects, there is limited data to support ivermectin use in
younger age groups (under 15 kg of weight).55 Additional
dose-ranging studies in young children would be needed to
help develop clear guidance for either the use for therapy or
prevention. Last, low ivermectin levels have been found in
breastmilk after treatment of a healthymotherwith ivermectin.
Given concerns about the maturity of the BBB in newborns
under 7 days of age, nursing mothers in the first week after
giving birth are currently excluded in MDA campaigns.
Areas known to be L. loa endemic have also historically been
excluded from ivermectin MDAs in onchocerciasis/LF programs
(e.g., areas of Angola, Cameroon, Chad, Ethiopia, and Gabon
among others), although screeningmethods are beginning to be
deployed. In patients with L. loa infection, the administration of
ivermectin can result in fatal encephalopathy if the individual
has an extremely high parasite density (> 30,000 mf/mL).
Figure 3 shows areas with overlapping endemicity for L. loa,
onchocerciasis/LF programs, and malaria. New diagnostic
tools for real-time screening of L. loawith a test-and-not-treat
TABLE 4
Main pharmacokinetic parameters for selected dosage schemes
400 μg/kg single dose 300 μg/kg on days 1–3
Onchocerciasis, 150–200 μg/kg
single dose
Moderate to severe scabies, 200 μg/kg
three doses within 2 weeks
Cmax 63.8 [44–88.5] 69.4 [34.1–196.3] 38 [35–41] 38.3 [27.8–52.1]
AUC 2,353 [1,313–4,169] 5,000 [1,600–8,300] 1,032 [874–1,210] 3,532 [1970–6,266]
Tmax 5.3 [3.9–7] 48 + 3.9 48 + [0.75–7.6] 5.6 29 [27.8–30.3]
AUC = area under the curve. PK model by Hammann. All parameters in median [range] Cmax: ng/mL, AUC: ng×h/mL, Tmax: hours.
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strategy are potential advancements to expandMDA to areas
traditionally excluded because of this risk.56
Additional studies on potential drug–drug interactions in the
context of ivermectin MDA for malaria vector control may need
to be assessed as several antiretrovirals and tuberculosis (TB)
drugs share the same metabolic pathway (p450 CYP) with
ivermectin,57 which could lead to 1) unexpected higher levels of
ivermectin or other commonly used drugs, such as anti-
retrovirals or anti-TB drugs, potentially causing toxicity or 2)
lower levels of ivermectin, antiretrovirals, or anti-TB drugs, thus
reducing efficacy. Until safety is proven, field trials might want
to consider using co-medication with these drugs as an exclu-
sion criterion.
Research and development agenda.
1. Independent safety reviews of the 1 × 400 database and 3 ×
300 regimen (ongoing).
2. Development plan for safety assessment under controlled
conditions before field trials or regulatory and policy review
of the 3 × 300 regimen.
3. Safety review in children under 15 kg and pregnant women
are ongoing. Modeling indicates that acceptable coverage
in the current eligible population will be reachable evenwith
exclusion of these populations, and none of the ongoing/
planned malaria trials include these populations. If needed
for either treatment or prevention for any indication, addi-
tional studies on the safety for use of ivermectin in children
< 15 kg and/or pregnant women would be required.
4. Current programs for MDA of ivermectin exclude visibly
pregnant women without pregnancy testing. Additional data
may be needed to support this approach early in pregnancy.
5. Creation of a pregnancy registry across all trials regardless
of dose or indication; with enhanced input of the NTD
community and an acceptable registry host.
6. Studies of drug–drug interactions between ivermectin and
other relevant drugs such as antimalarials, antiretrovirals,
and TB drugs.
Ethical considerations. As opposed to campaigns for
NTDs, in which ivermectin provides a direct benefit to indi-
viduals by reducing the parasite burden, MDA formalaria is an
intervention with an indirect community benefit and requires
careful attention to key ethical concepts in public health. Such
ethical considerations will be relevant both at the individual
level during clinical trials (i.e., study participants), and at a
broader level as the intervention advances to scale-up (i.e.,
country leaders, policy makers, civil society, academia, and
community leaders).
Although early data from limited studies suggest a direct
effect of ivermectin on Plasmodium liver stages in the host,31
other data contradict this finding, and therefore, the possibility
of individual protection requires validation. If it exists, the an-
tiparasitic activity seems to be minor, and is not yet well under-
stood. Thus, this report exclusively focuses on the ivermectin
indirect impact on human health at the population level as the
primarymalaria benefit of the intervention,without consideration
of the possible direct impact on the parasite itself.
The idea of indirect benefit through a delayed community ef-
fect is not unique to malaria prevention interventions. For ex-
ample, it has a precedent in the current efforts to develop a
malaria transmission–blocking vaccine.58 This concept also
echoes the “herd immunity” impact of live attenuated vaccines,
where vaccination provides benefit to those who remain un-
vaccinated, and extends beyond prevention of one individual.
Moreover, the community effect of an ivermectin MDA also has
parallels with IRS, where all households can be protected when
high coverage is achieved.
Ivermectin is a good candidate for an intervention with in-
direct benefits because of its overall safety profile previously
established through its extensive use against NTDs. However,
a risk-benefit analysis that considers the known risks of any
adverse effects and the benefit of lower chances of malaria
infection is a critical component of full policy analysis before
implementation of this strategy. Discussions with community
leaders and local health workers about the advantages and
limitations of ivermectin MDA will be required to ensure good
acceptability andcompliance, startingbefore theclinical trials.
From a communication perspective, it will be key to convey
simultaneously the idea that ivermectin, although it is a pill,
does not provide individual protection or treatment against
malaria, and therefore, clearly communicate that it is a com-
plement to vector controlwith ITNsand IRS. The fact that a drug
is being delivered might lead to certain confusion because it
can be interpreted as a treatment formalaria, which could result
in lower compliance with national malaria prevention and con-
trol measurements (e.g., use of ITNs, care-seeking behavior).
FIGURE 3. Overlap between selected Loa loa, onchocerciasis, andmalaria-endemic areas in Africa. (A) Estimated prevalence of L. loa eye worm,
(B) estimated prevalence of palpable Onchocerca nodules in the 20 African Programme for Onchocerciasis Control countries in 2011, and (C)
Plasmodium falciparum parasite rate in 2–10-years-old children in 2015.
10 IVERMECTIN ROADMAPPERS
For that reason, evaluation of the effectiveness of that com-
munication will be important. Ensuring that this is understood
at the community level will be critical for both NTDs and
malaria MDA programs, and will need effective, validated
communication tools during trials and beyond.
During clinical trials, all participants receive a clearly written
informed consent, with which they can accept or refuse to
engage in the study (this is extended to minors through their
guardians and even to livestock owners); all planned trials are
being conducted under national ethical review, often with
multiple layers of oversight. Importantly, the message that a
high coverage is necessary to achieve community protective
effect (i.e., greater than 80% of the eligible population, based
on modeling studies27,28) must also not be perceived as co-
ercive to any individual’s willingness to participate in the
program. Upon the transition to scale-up, the national plan
should aim for equity of access to the intervention under de-
fined parameters for priority communities.
One health. Current ivermectin veterinary indications for
horses, cattle, pigs, sheep, and small ruminant species include
the treatment and control of gastrointestinal nematodes, lung-
worms, and ectoparasites. Oral, topical, and injectable formu-
lations are available at a range of concentrations from multiple
veterinary approved generic producers.
In many rural African communities, herds are brought into
areas contiguous to human residence each evening, and their
blood sustains the Anophelesmosquito population, hence cre-
ating the opportunity for effective intervention with ivermectin. A
dual strategy providing ivermectin MDA to both humans and
livestockwill be particularly valuable in areaswhere bothmalaria
prevalenceandcattledensity arehigh, asdescribedby Imbahale
et al.24 (Figure 4). A coordinated ivermectinMDA to humans and
livestock could target zoophagic vectors that evade human-
centered approaches and, thereby, contribute to reducing the
residual transmissionofmalaria.Moreover, ivermectin treatment
will also directly benefit herds and their owners by reducing the
burden of other parasites, increasing productivity and, thereby,
improving overall living conditions of the communities.
A single veterinary ivermectin injection can last up to 6 weeks
and is typically used in high-income countries to treat entire
herds, but less frequently implemented in low-income settings.
Pharmacokinetic data show that ivermectin levels in cattle ca-
pable of killing > 95%ofAnopheles arabiensis in 10 days can be
sustained for 6 weeks after a single injection of 600 μg/kg with a
3.15% formulation (Ivomec gold® [Boehringer Ingelheim Animal
Health Argentina], which has a longer meat withdrawal period of
up to 120 days, preventing the use formeat for 3months).59 This
is important as the time frame in which mosquitoes become
infective after feeding on an infected person ranges from 10 to
16 days (hence, it is particularly important to reduce the pro-
portionofmosquitoes that reach this age). In pigs, a single dose
of 200 μg/kg with a 1% formulation of ivermectin can result in
1.5 weeks of mosquito-killing effect.40,60
Some of the factors determining the efficacy of livestock-
delivered ivermectin will be the livestock species and presence
(e.g.,surfaceareaof theanimal,variation in ivermectinmetabolism
byspecies, proximity of theanimals to humans, and the livestock/
human ratio), the local mosquito species composition, and the
local mosquito feeding preference (e.g., the degree of zoophagy
versus anthropophagy) as determined by blood meal analyses.
FIGURE 4. Areas where high cattle density coincides with high malaria prevalence in 2–10-year-old children (Inbahale et al).24
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All of these determinants require careful assessment with
human epidemiological endpoints in clinical trials before de-
ployment of ivermectin in livestock. In addition, the environ-
mental impact of the intervention and its programmatic
feasibility in Africa should be established in such trials. Addi-
tional risks such as alterations in mosquito behavior must be
investigated. For instance, a modeling exercise suggests that
in casesof twoormore vector species competing for the same
niche, intensive veterinary useof ivermectin could result in one
species shifting to more anthropophagic behavior (Dighe and
Slater, unpublished).
However, as a common veterinary drug, the safety of iver-
mectin in a number of animal species has been widely tested.
Exclusion criteria for livestock use would include milking
mothers and animals planned for slaughter within a defined
window according to established withdrawal periods for safe
human consumption of animal products (see section The
regulatory process for veterinary use).61
Ivermectin is the first-in-class endectocide currently
being experimentally evaluated in livestock as a proof of
concept to determine if this strategy might control malaria
transmission.12,22,23,62 Other endectocides can be deployed
in livestock, including eprinomectin, which has the remarkable
advantage of having a zero milk/slaughter withdrawal period.
Althoughuseof other endectocides in livestockmayultimately
be preferable to reduce selective pressure on mosquitoes or
reduce milk withdrawal times, ivermectin can be considered for
proof of concept trials. Along these lines, rotating or using live-
stock endectocides in mosaics could help prevent resistance in
mosquitoes or the primary target of these drugs, gastrointestinal
parasites in livestock. Ivermectin MDA for malaria prevention to
livestock poses, however, a series of similar challenges in the
areasof regulation, supplyanddelivery, environmental exposure,
as well as policy and financing, which will need to be carefully
assessed to determine the cost/benefit of campaigns targeting
both humansand livestock (see sectionRegulatory pathway and
policy recommendation pathway).
Research and development agenda.
1.Mapping ofmain livestock species to be targeted, including
veterinary/husbandry practices, where trials to evaluate
veterinary impact are planned
2. Scalable system for mapping livestock and relevant mos-
quito species where veterinary use is considered
3. Evaluation of impact of extensive MDA to livestock in evo-
lutionary selection of mosquitoes
4. Impact of veterinaryMDA on resistance to primary helminth
targets, drawing from experience where this has been al-
ready used extensively.
5. Potential use of endectocides without milk withdrawal times
such as eprinomectin.
6. Indirect risks and benefits of veterinary MDA, including
collateral production benefits
7. Environmental impact of veterinary MDA in the tropical
context.
Ongoing/planned trials. As of October 2019, there are at
least six clinical trials preparing to evaluate ivermectin MDA
against malaria either ongoing or under development. The
studies vary in design and will use several approaches for
community delivery of ivermectin, including synchronization
with other MDAs, combination with the administration of an-
timalarial drugs, and inclusion of treatment of livestock
(Table 5). Each trialwill havedistinct primary outcomesandwill
provide insights on different aspects of ivermectin MDA.
Although these studies are independent and individually
funded, the investigators are collaborating on critical design
and dose selection issues. Sharing information on the selec-
tion of primary and secondary outcomes of the trials and
having a common denominator to assess coverage of MDA
(e.g., census versus no census) would facilitate comparability
of results among studies and understanding the effect of
variable coverage on efficacy. Similarly, the methods for
monitoring resistanceshouldbecomparable across individual
trials. Creation of a database that incorporates data from all
the trials, including safety reviews and a registry for unplanned
pregnancy exposure, would be an important asset and could
help accelerate the policy and regulatory process. Last, co-
operation between researchers to coordinate how to present
and discuss the results to audiences, such as relevant country
stakeholders, the WHO, regional organizations, regulatory
authorities, would greatly facilitate further policy and funding
mechanisms for the implementation of ivermectin MDA, as-
suming positive trial results and a WHO supportive policy. In
addition, it will be important that the various communities and
organizations, including NTDs, malaria, non-governmental
organizations (NGOs), academia, and government, to name a
few, work through the learnings in implementation at each site
and the translation agenda to scale across geographies.
Assessment of expected impact. The potential health and
economic impact of ivermectin MDA in humans (cases and
costs averted) has been estimated using projections under
different scenarios (Chaccour et al., unpublished). This anal-
ysis assumes that the results from the funded BOHEMIA
clinical trials (i.e., BOHEMIA, see section Assessment of
expected impact) will be positive and followed by a WHO
policy recommendation on the use of ivermectin MDA for
malaria vector control. The model has been developed for the
TABLE 5
Trials using ivermectin to reduce malaria transmission through 2023 ordered by the time to first results
Trial name Lead researcher Country Dose Drug combination First results
MASSIVE Umberto D’Alessandro The Gambia 3 × 300 DHA-P MDA 2020
RIMDAMAL II Brian Foy Burkina Faso 3 × 300 Seasonal malaria
chemoprevention
2020
TBC Kobylinski and Sattabongkot Thailand 1 × 400 Ivermectin alone 2020
TBC Karine Moiline Burkina Faso N/A Ivermectin to livestock 2020
TBC Anna Last Guinea-Bissau 3 × 300 DHA-P MDA 2021
BOHEMIA Rabinovich and Chaccour Tanzania and
Mozambique
1 × 400 Ivermectin alone +
ivermectin to livestock
2021 and 2022
DHA-P = dihydroartemisinin–piperaquine; MDA = mass drug administration; N/A = not-applicable.
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period of 2023–2027 with assumptions that clinical trials will
produce supporting evidence by 2022 that the results and
intervention will be acceptable to the community and that
additional funds are available for translation and imple-
mentation at scale in a number of African countries. The pro-
jection of impact of a 400 μg/kg single dose was made under
the following conditions:
1. A group of 20 African countries were identified as potential
first implementers based on the burden of malaria, lack of
drug contraindications, and current political stability. The
selected countries were classified as early (2023) or late
(2025) implementers, based on their previous experience
with ivermectin programs for other indications.
2. Uptake was conservatively defined as piloting districts
encompassing at least 5% of the country’s population at
risk with a 3% increase yearly (conservative estimate of
uptake based on the SMC program). In these districts, the
target coverage of the intervention was 80% of the eligible
population (i.e., only including non-pregnant women and
children above 15 kg) or 64% of the general population.
3. The potential efficacy of the ivermectin MDA regimen was
defined as 20% reduction in clinical incidence (minimally
required criterion in WHO’s PPC) or 40% (projected esti-
mate based on modeling).
4. Ivermectin is expected to have important synergies with
current core vector control tools (i.e., ITNs and IRS) by re-
ducing mosquito biomass. A very conservative 5% cumu-
lative reduction in cases was factored in as current models
cannot predict synergies (i.e., 5% of the predicted cases in
any year do not occur in the next year).
5. The reduction in malaria cases was adjusted to four po-
tential global scenarios based on the work of Griffin et al.63
for the GTS (WHO GTS).5
6. Financial cost savings were calculated using the final figure
of cases averted and the average cost of non-complicated
and complicated malaria cases in Africa,64 applied to either
1 or 3% of cases as “complicated.”
7. Intervention costs were calculated using preliminary final
dosage form (FDF) cost and the delivery costs based on
published figures for ivermectin delivered as a single dose
for NTDs.
8. Final savings and costs per case averted were calculated
with the above data.
Figure 5 shows the predicted changes in clinical malaria
incidence under the four Griffin scenarios: Sustain, Accelerate
1, Accelerate 2, and Innovate for the selected 20 early in-
troduction African countries. The dotted lines show the addi-
tional impact attributable to an ivermectin MDA, considering
the minimum required efficacy of 20%, as well as the alter-
native estimated efficacy of 40%. Taking these results into
account, further calculations predicted that the intervention
could avert between 11,000 and 65,000 deaths, and between
5.2million and 32million cases from 2023 to 2027, resulting in
cumulative averted financial costs betweenUS$32million and
US$208 million.
Resistance.Broad community deployment of ivermectin to
reduce malaria transmission has the potential to enhance the
impact on diseases already treated with this drug, such as
onchocerciasis, LF, and scabies, but it also runs the risk of
generating resistance in someNTDs, as well as inmosquitoes
FIGURE 5. Malaria incidence per 1,000 population at risk in 20 selected countries during the 2018–2027 period and calculated additional impact
attributable to the BOHEMIA intervention from 2023–2027.
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and veterinary parasites. Therefore, any approach to using
ivermectin MDA against malaria should take into account that
the current (2019) and evolving primary indications of the drug
must be protected while designing strategies that minimize
the ability for mosquitoes to develop resistance.
Resistance to current indications. There are valid concerns
about increasing selective pressure on filariae with wider use
of ivermectin, but this risk is not well documented. Reports
of ivermectin-resistant Onchocerca have been the subject of
debate.65–68 These reports refer to suboptimal response
against Onchocerca with persistent microfilaremia and early
repopulation. The balance of evidence suggests that pres-
ence of suboptimal response does not threaten the control
of onchocerciasis as a public health problem. Moreover,
as part of the risk mitigation strategy for filarial resistance,
triple therapy with albendazole–diethylcarbamazine (DEC)–
ivermectin has showndramatic impact at killing thewormafter
2 years of treatment and will likely become the new approach
for LF eradication.
Ivermectin is also under evaluation for MDA against soil-
transmitted helminths (STHs) because adding ivermectin will
increase the impact of deworming programs by targeting
Strongyloides, which is not affected by albendazole-based
programs. The risk of resistance inSTHhasbeendescribed as
higher than for filariae, although risk mitigation strategies are
alsobeing considered.Combination therapyof ivermectin and
another anthelmintic to increase the effect onpartially affected
parasites, such as Trichuris, could lower the risk of re-
sistance.69 Furthermore, the concerted application of water,
sanitation, and hygiene programs along with antihelminthics
in STH areas are functional resistance risk mitigation strate-
gies because impact is generated via an alternative route.
The dose and regimens proposed for malaria are higher
and/or more frequent than that indicated for some NTDs
(higher than filariae, lower than those under consideration for
STHs), which could have a larger impact on the overall bio-
mass of filariae circulating on certain areas, effectively re-
ducing the number of parasites exposed to the drug in the
longer term andmaking thewindowof selection for resistance
narrower.
The primary purpose of veterinary ivermectin (and most
other endectocides) is to enhance agricultural production by
improving livestock health. The efficacy of ivermectin against
endo- and ectoparasites of veterinary importance should be
monitored in the context of a more intensive, albeit intermit-
tent, use for malaria.
Mosquito resistance. Note that mosquitoes have sporadi-
cally received low concentrations of ivermectin for decades at
a massive scale through MDAs against NTDs. No obvious
evidence of resistance to ivermectin has been seen to date,
although limited testing hampers the ability to draw conclu-
sions from this absence of evidence. However, the potential
emergence of resistance to ivermectin in malaria vectors
needs to be carefully monitored and risk mitigation strategies
created before the implementation of ivermectin MDA.
To date, ivermectin drug-class resistance in arthropods of
human and veterinary importance has been associated with a
wide range of mechanisms: reduced cuticular penetration,70
mutation of the target, glutamate-gated chloride ion chan-
nel,71 accumulation of GABA,72 andmetabolic resistance due
to overexpression of xenobiotic pumps73,74 and cytochrome
P450 isoenzymes.74,75
The available data on ivermectin cross-resistance with py-
rethroids is conflicting. In some studies, permethrin-resistant
houseflies, cockroaches, and head lice were susceptible to
abamectin or ivermectin.76–79 In other studies, permethrin-
resistant cockroaches, houseflies, and Aedes aegypti mos-
quitoes were less susceptible to abamectin or ivermectin.80 In
addition, ivermectin tolerance mediated by transcription of
P450s and xenobiotic pumps can be induced in ticks, head
lice, and Drosophila melanogaster.81–83 Overall, this suggests
that differential mechanisms of ivermectin tolerance and re-
sistanceoccur and that cross-resistance is alsopossible via at
least one of these mechanisms.
Based on observational studies, ivermectin MDA has
proven effective even in areas with high levels of pyrethroid
resistance among Anopheles,84 but increased selective
pressure from repeated dosingmay change this. Thus, urgent
attention should be placed on characterization of how
Anopheles could develop tolerance and resistance to iver-
mectin. This research could identify molecular markers for
surveillance that would indicate population susceptibility or
rising resistance to ivermectin. However, molecular markers
are only associative, and so phenotypic studies (mortality
assays with wild-type Anopheles) should also be periodically
conducted, particularly in areas with evidence of ITN effec-
tiveness decay.
In the context of livestock treatment, ivermectin has been
shown tobe able to stay active in thewholewater systemup to
127 days.85 Mass cattle treatment could expose mosquito
larvae in their aquatic habitat via cattle defecation. This could
expose both zoophagic and anthropophagic Anopheles, as
their larval habitat during the rainy season are formed from
accumulationof rainwater in animal hoof prints, small puddles,
ponds, and temporary animal watering holes, all of which are
often contaminated with livestock excreta. The longer resi-
dency time of endectocide in injected cattle also increases the
window in which adult mosquitoes may imbibe sublethal
concentrations, with the potential increase in resistance as
susceptible populations are slowly reduced by the drug.
Until molecular markers of resistance are identified and
developed into a validated assay, susceptibility testing in
mosquitoes will have to rely on one or more common phe-
notypic assays, such as feeding ivermectin in a blood meal or
sugar water to adult mosquitoes. This would require well-
characterized standards of serum (frozen or lyophilized) or
sugar solution that could be shipped to all sites and applied in
a standard way to local F1 or F2 generation mosquitoes. The
amount of work to overcome local variability in mosquito
rearing, willingness to blood feed through amembrane, etc., is
not trivial, but developing common approaches and standard
operating procedures (SOPs) for resistance monitoring strat-
egies could provide critical early warnings andmake it feasible
to more easily generate comparable data at multiple sites.
Theoretically, a rudimentary approach to identifying re-
sistance markers is to force resistance in laboratory colonies
of one or more Anopheles species. The approach is to give
blood meals with increasing, sublethal doses of ivermectin
and metabolites to each generation until resistance is ob-
served. Establishment of ivermectin-resistant Anopheles
colonies is complicated by the fact that sublethal ivermectin
concentrations can still inhibit fecundity. If successful, geno-
mic tools could then be used to identify resistancemarkers by
comparison of parental and selected mosquito strains albeit
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with the known limitations in external validity of resistant col-
onies generated in the insectary.
Ideally, it would be useful to incorporate a common strategy
to monitor ivermectin susceptibility at the baseline and end of
field MDA trials to determine resistance development over the
course of time. Simple approaches for monitoring include
using sugarmeals with ivermectin to detect potential changes
in the LC50. If phenotypic changes are found from tests before
and after interventions and compared with untreated areas,
these samples could be molecularly tested to try and un-
derstand the genetic basis for resistance.
Resistance risk mitigation strategies. The risk of resistance
emergence in mosquitoes after veterinary application needs to
be acknowledged, discussed, and monitored. Several risk mit-
igation strategies have beenproposed. The creation of refugia86
(untreated populations) could be a useful approach to manage
resistance risk for veterinary parasites, which de facto would be
implemented by the proposed selection criteria for treatment
(exclusionofmilkand/or soon-to-market livestockaspercurrent
regulations). An alternative strategy discussed would be to im-
plement ivermectin in mosaics within herds or by using a dif-
ferent endectocide class in an area where humans receive
ivermectin.Refugiawouldsimilarlybecreated in implementation
of human ivermectin MDA, given the indicated exclusion of
young children and pregnant women from MDA campaigns.
To prevent mosquito resistance, early research into optimal
combination with other vector control approaches should be
performed; in addition, attention to other potential uses of
ivermectin, both forNTDsaswell asmalaria, that could increase
the exposure and hasten the appearance of resistance, such
as ivermectin-based sugar baits87,88 or wall linings,89 should
be discussed and evaluated as part of risk management.
In summary, ivermectin MDA in humans and relevant veteri-
nary species is proposed as a complementary vector control
strategy, and all trials to evaluate its impact on malaria are oc-
curring in the context of ITNs, with or without IRS. As a result,
ivermectinwouldbepartof combinatorial strategieswithmultiple
routes to their mosquito targets (via direct cuticular contact,
bloodmeal, or sugar ingestion) and with complementary modes
ofaction that shouldall limit resistancedevelopmentamongboth
intestinalparasitesandvectors. It follows thateachcomponent in
a combination strategy should have differential modes of action
to help preserve the others. Given that ivermectin is the only safe
and registered endectocide available to humans at this time and
for the foreseeable future, and that it is designated an essential
medicine by the WHO as an NTD tool, efforts should be put in
place topreserve itsNTDactionanddecrease the riskofpotential
resistance in human parasites and mosquitoes.
Research agenda.
1. Develop the right tools to monitor resistance in other target
organisms such as filariae and STH by the NTD community
2. Investigate whether ivermectin has important cross-
resistance with other vector control tools (i.e., resistance
to pyrethroids)
3. Generate a standard ivermectin susceptibility assay for
mosquitoes
4. Continue active monitoring of vector resistance status
throughout malaria MDA ivermectin campaigns
Environmental impact. Theenvironmental impact of intense
ivermectin use in livestock has been extensively documented
in places of large-scale use against helminths in Europe and
theUnited States. However, there are limited data of the use in
tropical regions in the context of African small-holder herding
practices. In addition, there are no data on the environmental
impact of mass administration of ivermectin to humans. There
are reasons to posit that this would not be higher than in
temperate regions because of the effect of higher temperature
and humidity that would hasten drug degradation. On the
other hand, the environmental impact is dependent on the
relative susceptibility of flora and fauna in specific tropical
versus temperate areas, which are presently unknown.
Overall, environmental safety and impact are important steps
in the evaluation process of vector control tools.
Following veterinary administration, ivermectin and its me-
tabolites are excreted in feces and may enter into different en-
vironmental compartments (e.g., dung, soil, surface water, or
groundwater). Dose and route of administration of ivermectin,
aswell as diet, affect the levels of ivermectin and itsmetabolites
in the feces, whereas environmental factors such as climate,
population density, soil type, vegetation, and waste manage-
ment practices influence how long these compounds persist in
the environment in addition to where and how they accumu-
late.85 Ivermectin can persist in the dung of treated livestock for
weeks tomonths, potentially affecting nontarget insects, many
of which are dung-dwelling species considered essential for
dung degradation. Ivermectin and its metabolites can also ac-
cumulate in soil and in water because it is not readily bio-
degradable inaquatic systems.Although thisdrug isnot toxic to
mammals, microorganisms, or plants, it can be toxic to aquatic
invertebrates (i.e., Daphnia magna), algae, and fish.87
Finally, the NTD experience shows that the pharmaceutical
industry gives great importance to the appropriate disposal
(via incineration) of expired medicines. Plans to do so need to
be embedded in the malaria MDA trials and, later, would need
to be built into implementation plans.
REGULATORY PATHWAY AND POLICY
RECOMMENDATION PATHWAY
Ivermectin has been licensed since the 1980s to treat a
number of parasitic helminths in both humans and animals. Its
use atmassive scale for NTDMDAprogramshas beenunder a
donation model with product approved under WHO-defined
stringent regulatory authorities. Although ivermectin is listed
on the WHO Essential Medicines list and WHO has had an
open invitation to manufacturers for submission of ivermectin
for prequalification (which is specific to the manufacturer,
even for a generic product), there are currently no prequalified
ivermectin producers. This is likely due to the donation model
for onchocerciasis and LF, the current primary applications at
large scale (see section Manufacturing and procurement),
whereas generic manufacturers do provide ivermectin for
treatment under national regulatory approval in various coun-
tries. Thus, repurposing ivermectin for malaria vector control
and other pending applications will require, beyond a WHO
policy recommendation for its use for malaria control, WHO
prequalification of any product that is not approved by a strin-
gent regulatory agency asdefinedbyWHO, toallow for national
procurement with funds from multilateral or bilateral donors.
Prequalification, defined further in the following paragraph, can
be given in the context of a range of indications and, thus,
serves as a pathway to approval for a new indication.
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Regulatory pathway for use as a malaria vector control
intervention for human malaria. A policy recommendation
for ivermectin by WHO will require a thorough review across
several departments of the agency, including the disease-
specific programs good manufacturing practices (GMPs) and
NTD and their respective advisory committees (i.e., MPAC,
vector control advisory group [VCAG], as well as the pre-
qualification team [PQT], and essential medicines, among
others). The evaluation system for new vector control tools,
which was revised in 2017, can be divided in four general
phases: pre-submission, new intervention pathway, parallel
GMP/NTD department assessment (through MPAC for
malaria/STAG for NTDs) and PQT inspection, and post-
recommendation activities (Figure 6, Table 6).90,91
Phase 1: Pre-submission.The first stepof the assessment is
the pre-submission of the proposed clinical trial and/or draft
product label to a single-entry portal managed by PQT. The
feedback from the PQT will determine the evaluation pathway
that a potential vector control tool must follow 1) Pre-
qualification Pathway (i.e., if the product is part of a class with
an existing WHO policy recommendation), or 2) New In-
tervention Pathway (i.e., if the product does not belong to a
class with an existing WHO policy recommendation). Ac-
cordingly, the consideration of a new indication for malaria
control will fall under the New Intervention Pathway,91 thus
requiring the need to evaluate its health value as well as other
parameters, including mosquito impact and overall safety.
To allow for VCAG’s review of the evidence generated,
manufacturers and research groups currently working on the
subject are invited to take protocols specifically to VCAG for
detailed review before generating the evidence.
Phase 2: New Intervention Pathway. The New Intervention
Pathway is managed by the GMP and NTD, with a single-entry
pathway for VCAGandothers to perform the assessment of the
product dossier.92 Advicewill be given to the applicant in terms
of data required, trial design, risk assessments, and product
specifications. In addition, VCAG will provide feedback on as-
sessment standards and requirements (i.e., SOPs, quality and
safety standards, etc.) through periodic interaction with the
applicant. Because ivermectin is a drug, VCAG reviewwill likely
include other relevant expertise, including drug prequalification
for drug safety and participation of NTD and GMP staff.
Vector Control Advisory Group’s guidelines state that a
requisite for a policy recommendation is to show an epide-
miological proof in at least two randomized controlled trials
conducted in two different settings with data collected across
two consecutive transmission seasons.93,94 Additional rec-
ommendations by VCAG for the design of research studies,
based on the input to other products reviewed, may include
the following:
1. Early development/standardization of means of testing for
resistance (both in vectors and in endoparasites)
2. Data on residual efficacy in feces and other environmental
safety issues (nontarget organisms)
3. Risk assessment
4. Data on vector population recovery times and the duration
of effect needed to sustain/achieve long-term population
reduction
4. Strong community engagement strategies
5. Product pricing, deployment plans, and costing are not a
requisite, but cost-effectiveness assessment is relevant to
inform formulation of a policy recommendation
6. Stringent regulatory approval could facilitate product reg-
ulatory approval in endemic countries, but policy recom-
mendation from WHO is on the critical path for the malaria
indication as well as policy recommendation in countries
Phase 3: MPAC assessment/policy recommendation. After
a positive recommendation on the value of the product from
VCAG as a vector control tool, it will be further evaluated by the
corresponding policy advisory committee for malaria (MPAC). In
parallel, following a manufacturer request for prequalification,
PQT conducts a formal review and/or inspection of the
manufacturing facilities to ensure compliance with quality stan-
dards. This process should include an evaluation of the pro-
grammatic suitability and of the operational research agenda.
Givensatisfactory resultsofbothprocesses,WHOwill then issue
a policy recommendation and the product will become “first in
class.”Operationalguidelines for implementationwill be released in
parallel to the policy. However, prequalification of the product will
be based on the assessment and, although the policy refers to a
generic product, the prequalification approval will be linked to
specificmanufacturer’s facilityevaluation for ‘GMP’aswell asother
technical evaluationsofproduct.Because this is thefirst drug togo
through VCAG, the process may be tailored to generics.
Phase 4: Post-recommendation/post-prequalification activities.
This phase refers to the plan andwork needed at the country level
for issuing national policies based onWHO’s recommendation, as
well as the requirements forproduct registration, procurement, and
implementation at scale. In addition, continuous inspection of
product quality and manufacturing facilities will be performed by
the PQT.
Action Items.
1. Engagewith VCAGas an entry point for guidance before the
trials to ensure that methods and data comply with their
requirements
2. Enhance communication across clinical trial groups to en-
sure comparable key endpoints across trials to provide
VCAGand regulatory bodieswith a robust bodyof evidence
3. Develop a pathway assessment for country trial to policy
and implementation steps following country evidence of
ivermectin impact
Regulatory process for veterinary use. For malaria, mass
use of endectocides in livestock has a dual pathway for
evaluation and approval. Whereas global health authorities
review the efficacy endpoint (i.e., reduction of malaria trans-
mission) and product quality, animal health authorities are
responsible for the regulatory approval of the intervention for
FIGURE 6. Steps in the WHO evaluation system for new vector control tools.
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veterinary use (i.e., a specific dose, regimen, or formulation)
and for its overall effect on animal health. In addition, the useof
drugs in animals raised for human consumption is assessed
by the international Joint FAO/WHO Expert Committee on
Food Additives and the Codex Alimentarius Commission.
These bodies define the acceptable daily intake of the drug
and the appropriate withdrawal times for milk and meat con-
sumption according to the dose/regimen selected and to the
livestock species being treated (Table 7).
In the case of ivermectin MDA in livestock, the proposed
dose and formulation are already approved, and the product is
available. This class of products is licensed under stringent
regulatory authorities, and there are licensed veterinary for-
mulations already approved in many malaria-endemic coun-
tries. The pathway to policy recommendation for veterinary
use for malaria may require review of the WHO malaria rec-
ommendations and engagement with the WHO health com-
munity by the FAO, but this will probably adapt to the unique
requirements of ivermectin as an existing drug with multiple
applications for veterinary endpoints.
TRANSITION AND IMPLEMENTATION AT SCALE
If the effectiveness of ivermectin MDA against malaria is
proven and achieves a WHO policy recommendation, addi-
tionalworkwill be needed to facilitate country introduction and
implementation at scale. The transition to scale-upwill include
activities such as the inclusion of the concept of intervening in
residual transmission in the national strategic plans; evalua-
tion and development of sustainable delivery models appro-
priate to country context; determination of appropriate
entomological and epidemiological monitoring and evaluation
strategies; engagement with key stakeholders at global, re-
gional, and national level; and engagement with generics
manufacturers as suppliers in the context of a high-volume,
low-pricemarket.Modeled on the introduction of antimalarials
for community prevention of malaria (i.e., SMC andMDA), it is
assumed that the initial roll outwill begin in a subset of districts
or provinces of a group of early introducer countries. Pre-
sumably, the earliest implementers would be those countries
experiencing significant levels of residual transmission in
which clinical trials were conducted.
TABLE 6
Summary of the WHO prequalification process for new vector control tools91
Phase Primary outcome Steps Factors Pathway designation
Pre-submission Define evaluationpathway Pre-submission to PCC Pre-submission
coordination
committee
Pathway designation
New interventionpathway Validated public health
value of product class
Concept review and data
definition
VCAG Defined data required to
validate public health value
and support a WHO policy
recommendation
Development of
assessment standards
VCAG product
developer
Developed efficacy test
guidelines, SOPs, quality
and safety standards, and
criteria
Manufacturer-led data
generation
VCAG product
developer
Clinical trial results
PQT inspection PQT product
developer
Report from manufacturing
facility inspection
Data assessment and
recommendation to
MPAC
VCAG Final VCAG report to MPAC
Good Manufacturing
Practices/Neglected
Tropical Disease/PQT
Assessment
1) Policy recommendation
issued 2) Product
prequalified
MPAC/STAGassessment MPAC MPAC meeting report
PQT assessment PQT Product listing
Post-recommendation
activities
Programmatic use Country health authority
review
MoHs NMCP Country policy issued
Country regulatory review MoHs Reg. authorities Product registered in country
Country procurement MoHsGFTAM/UN/PMI Product procured by
countries
Country use MoH NMCP Roll out and monitoring
Post-PQT activities Ongoing inspections and
assessments
Post-PQT activities PQT
MPAC = Malaria Policy Advisory Committee; PCC = preferred product characteristics; PQT = prequalification team; VCAG = Vector Control Advisory Group.
TABLE 7
Withdrawal times for slaughter (WDI) or milking (WDT) in animals
treated with ivermectin * FDA approved withdrawal times
Livestock species
route of administration
Ivermectin dose
(mg/kg body weight)
Meat WDI
(days)
Milk WDT
(days)
Cattle
Subcutaneous 1% 0.2 35* 47
Subcutaneous 3.15% 0.6 120–140 N/S
Oral 0.2 24* 28
Topical 0.5 48* 53
Swine
Subcutaneous 0.3 18* NA
Oral 0.1 5* NA
Sheep
Oral 0.2 11* NA
Goats
Subcutaneous 0.2 35 40
Oral 0.2–0.4 14 9
Topical 0.5 NA 7
NA = Not available. Other values based on Food Animal Residue Avoidance Databank–
recommended withdrawal intervals.
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Thus, the WHO policy recommendation is critical, but im-
portant work to translate the recommendation as a new in-
tervention to country-led programs should be planned for in
parallel to evidence creation, particularly as data emerges on
efficacy in the various trials. Ideally, timely guidance from
WHOonwhat additional information is needed is an important
part of the process. For example, consideration is needed as
to how ivermectin would be optimally incorporated within the
package of existing interventions.
Given potential programmatic synergies, collaboration with
the well-established NTD programs will be key to national
implementation plans to enhance impact as well as avoid any
competition for sharable resources (e.g., staff, transportation,
etc.). However, key aspects such as drug regimens (i.e., single
dose annually for onchocerciasis and LF versusmultiple times
a year for malaria), timing of the intervention (i.e., malaria
control would be distributed during the rainy season, whereas
NTD is not limited and moreover often optimally delivered in
the dry season, when transport is easiest), and supply chains
(i.e., procured versusdonated) need tobecarefully considered
in the creation of country plans. Subnational mapping of pri-
ority target areas may be different for both indications.
In any case, the distinction between ivermectin to treat
NTDs and to control the malaria vector needs to be clearly
conveyed to the targeted communities. Data and learnings
from the various clinical trials on how to best communicate
that ivermectinMDA is a drug to kill themosquito, but is not an
antimalarial, should be an additional point of collaboration in
the clinical trial phase that can be applied to scale-up post-
policy recommendation.
Last, financing of ivermectin MDA by multilateral agencies
such as the Global Fund or bilaterals such as PMI will likely
require a recommendation fromWHO, an adoption by national
malaria strategic plans, and either first tier-approved or pre-
qualified product. Thus, part of the work required for imple-
mentation at scale will focus on the accomplishments of these
key milestones (see section 5.5 for financing).
Manufacturing andprocurement.Current onchocerciasis
and LF programs are based on the donation of ivermectin by
the pharmaceutical companyMerck to theMectizan Donation
Program. The corporation has recently announced a new
commitment to include ivermectin in triple therapy for LF
through 2025,whichwill increase the demand for the donation
program over the next decade. For the donation program,
prequalification is not required because Mectizan is a strin-
gent regulatory approved product (e.g., by the FDA and EMA).
Although the donation program has provided enormous
health benefits, the model has limited the investment incen-
tives for other manufacturers to supply the drug for limited
therapeutic indications. As a consequence, although iver-
mectin is on theWHOEssential Medicines list, no product has
yet been prequalified (as of October 2019).
A policy recommendation for ivermectin MDA against
malaria would help build a high-volume/low-price generics
business case for manufacturers because it will result in the
potential need for procurement by malaria donors and/or
country governments of billions of additional ivermectin tab-
lets over the next decade. This would create a business in-
vestment case for generic manufacturers to seek WHO
prequalification to support countries to request international
funds for theprocurement of thedrug. In addition, thepotential
inclusion of other new indications such as the treatment or
MDA to control scabies95 (recently included as an NTD by the
WHO96) and ivermectin MDA with other drugs for STHs95
would bolster the generics business case. Given the constant
evolution of the NTD landscape and emerging uses of iver-
mectin, the global supply needs for the drugwill require careful
tracking and anticipation to meet future and realistic demand
projections.
The good news is that as an established generic product,
production of ivermectin is streamlined as the drug is manu-
factured at ambient temperature, with available film-coating
processes, and is technically scalable, as has already been
demonstrated by the donating manufacturer. As a generic
drug, scalable production protocols and testing procedures
are both publicly available (e.g., a bioequivalence study pro-
tocol has been recently published by WHO). In addition, there
are several manufacturers of active pharmaceutical ingredi-
ents (APIs) with self-reported productions above 50 tons per
year.18 Most of the global manufacturing of APIs is of veteri-
nary grade, whereas the process for human APIs requires
additional quality controls and documentation. As guidance,
only around 2.5 tons of APIs per year are needed to treat 180
million people with the current single-dose onchocerciasis
regimen, and thus, the pathway to increased supply can be
managed if the increase in demand is communicated, plan-
ned, and phased.
There are a number of generic companies in Europe, Asia,
Latin America, United States, and Africa that produce other
drugs under GMP, withWHO and/or SRA (e.g., FDA and EMA)
reviewed and approved facilities. Given the potential interest
by genericsmanufacturers in newmarkets at high volume/low
price, the timeline to go frompositive trial results to availability,
in the context of already GMP/qualified active ingredient,
would be relatively short.
Technically, it would also be feasible to manufacture
18–20 mg tablets as single dose for adults, and this would
make dosing more effective and potentially cheaper at scale.
Additional work to demonstrate the potential value, the impact
on supply chain management and procurement, as well as to
build the investment case for this tablet size would likely be
required. Although a pediatric formulationmay be important in
the long term, it will require further development and it is not a
current priority because children < 15 kg do not receive this
drug for malaria MDA or any other control campaigns. How-
ever, pediatric interest could increase if scabies or STHMDAs
are approved and implemented at scale because it would
broaden the eligible population.
Finally, in terms of procurement and management of the
drug, the current label states that storage should be under
30C up to 3 years; however, it is handled with fewer restric-
tions at final delivery by existing programs. Theremaybevalue
in evaluating the supporting data, as well as the stability and
programmatic suitability of the specific formulations used.
Interactions with NTDs and other national programs.
Assuming the ongoing trials provide evidence that ivermectin
MDA for malaria has a robust effect, it will be critical to begin
collaborative approaches with the national NTD programs to
develop models for delivery. The lessons learned from 30
years of ivermectin MDA deployment should guide the com-
plex operational aspects of scaling-up the use of ivermectin
under the new indication. Moreover, insights from other
malaria MDA trials and programs, including SMC and ACT
MDA, should be also considered. Emerging MDA programs,
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such as azithromycin to reduce overall child mortality,97 and
other national campaigns such as immunization, may also
need to be considered for synergy and operational alignment.
Given the extensive geographical overlap of malaria- and
NTD-endemic areas (Figure 3), there are a number of potential
health and operational benefits as well as challenges for a
national ivermectin platform targeting multiple diseases, and
both will need to be actively discussed by program leaders.
For instance, ivermectin NTD programs could benefit from an
enhanced impact due to the delivery of a second annual dose
of thedrug, a strategy that hasbeen recommendedbut still not
well implemented. In addition, wheremalaria extends to wider
areas than NTDs, the malaria program could create buffer
zones around areas targeted for onchocerciasis/LF elimina-
tion, preventing the reintroduction of infections. This strategy
has proven successful in West Africa as part of the Oncho-
cerciasis Control Program.98
Among the challenges of dual ivermectin programs is the
current misalignment of the dose and regimen, as well as
product source (i.e., one donated and the other purchased),
for drug distribution. The ivermectin dosage proposed for
malaria is higher than the one for onchocerciasis control, al-
though the 400 x 1 dose is within the range recommended for
LF. Moreover, the regimen under evaluation for malaria is not
only more frequent but also time sensitive to the mosquito
proliferation around the rainy season. However, an approach
recommended to address suboptimal response (i.e., rapid
return of microfilaridermia after treatment) in Onchocerca
volvulus infections is to increase the frequency of ivermectin
delivery from annually to every six or 3months,99 although this
is not broadly implemented given isolated existence of sub-
optimal response. Ideally, the higher ivermectin dose for
malaria should be sufficient to cover both vector control and
NTD strategies. Nevertheless, additional work would be
needed to understand and plan for co-administration of other
drugs such as DEC or albendazole with ivermectin to satisfy
other disease requirements.
Prior experience with community deployment for NTDs
originally started using costly mobile teams, and then drug
deliverywas transferred to village health workers and, through
a greater involvement of the communities (i.e., community-
directed), with village volunteers minimally supervised by
government personnel.100 However, this annual volunteer
approach may not be appropriate for three sequential,
monthly ivermectin campaigns for malaria. Moreover, in pla-
ces where both malaria and NTD programs co-exist, trans-
parent roll out of two different sources of ivermectin and an
agreed on mechanism for distribution and communication
strategies will be needed. Preliminary engagement of leaders
at global and national levels indicates strong support for
consideration of complementary strategies.
Stakeholder engagement and community uptake. En-
gagement with different stakeholders will be critical from the
planning of clinical trials through to the establishment of sus-
tainable delivery programs. The range of relevant stakeholders
will vary according to the phase of the effort and to established
countrypartners in themalaria,NTD,Maternal andChildHealth,
andveterinaryprograms. “Stakeholder” is abroadumbrella that
includes local and national government, academic, and civil
society leaders; in-country NGOs; journalists; and potentially
NGOs of relevance, such as RTI, Sightsavers, MSF, CHAI, and
others. Similarly, funders can include bilaterals (e.g., PMI and
DFID), multilaterals (The Global Fund, UNICEF, and other UN
agencies), and national funds. Specifically, designing the na-
tional malaria strategies and the post-policy roll out of the
interventionwill represent crucialmomentswhere stakeholder
engagement will be instrumental for country ownership, as
well as for leveraging and strengthening the capacities at the
institutional and community levels.
Given the uniqueness of the intervention, in which a known
drug is used to reduce malaria transmission through an in-
direct, community effect, the acceptability by community
members will drastically affect uptake and coverage. Collab-
oration between in-country institutionswith previousoutreach
experience and community leaders will be important. As early
as at clinical trials stage, formative research will help un-
derstand the factors influencing theacceptability of ivermectin
for malaria as well as how to effectively convey the vector
control nature of the intervention.
Funding. Besides the health impact of the intervention,
cost-effectiveness analyses will be an important driver for
countries and funding agencies to support the use of iver-
mectin formalaria control. Clinical trials should be designed to
provide economic data for this analysis, although comple-
mentary modeling exercises can help estimate the cost of
implementing ivermectin MDA in real settings, including de-
livering the drug to humans only and to humans and livestock.
The key opportunity is to examine the results from different
clinical trials as they emerge to approach funding bodies in ad-
vance and facilitate program launch after a WHO policy recom-
mendation, aswell as to assure ivermectin supply. For instance, a
WHO recommendation is a prerequisite for submitting proposals
to the GFATM, but time to approval will depend on when in the
cycle of funding a country request ismadeandwhether countries
include residual transmission plans in their strategic plans.
Therefore, parallel briefings to national malaria control programs
(NMCPs) on projected study design and timelines to emerging
data, for consideration of inclusion of general language related to
interventions to address residual transmission in national strate-
gicplanningasearlyaspossible,will beparticularlyuseful forearly
introduction countries. This intervention may also be relevant to
otherpotential sourcesof funding, includingnational funds,World
Bank loansor grants, implementingNGOs, andbilateral agencies
supportingmalariaprograms.Briefingsasdataaregeneratedand
the impact case is refinedwill facilitate translation to scale once a
policy recommendation is available. In addition, an adaptive
mapping of the timings for regulatory approval, policy recom-
mendation, ivermectin demand creation, and final costs of
implementation, among other aspects, will be key to inform
manufacturers and funding bodies.
An analysis of different funding bodies and specific re-
quirements for each of themwould facilitate the process. This
is particularly true for potential funding of veterinary products
because careful analysis and presentation will need to clearly
present the value proposition for malaria programs, and the
source of funding is not clear at this time.
Research agenda.
1. Projections of ivermectin demand and supply taking into
account other NTD indications as well as malaria control
2. Creation of a rigorous business case for ivermectin
manufacturing and country supply, including demand pro-
jections to facilitate industry engagement and supply of pre-
qualified ivermectin at a generic pricing structure
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3. Reassess ivermectin shelf life (currently labeled as 3 years)
and whether additional heat stability studies are needed for
storage above 30C degrees
4. Assess the potential for single dose indication and
formulations
5. Potential for alignment of malaria and NTD control pro-
grams, as well as other national health campaigns
6. Analysis of most cost-effective integrated delivery system
options in collaboration with other programs
7. Development of effective communication tools regarding
the vector control nature of the intervention
8. Evaluation of the health and economic impact of interven-
tion in the longer term
CONCLUSION
The Roadmap illustrates the pathway to assess the poten-
tial repurposing of ivermectin as a complementary vector
control tool for malaria and its subsequent large-scale
implementation. Given the complexity of the overall process,
the different actions and steps required from proof of concept
to field deployment have been carefully described here. As a
summary, Figure 7 provides a visual representation of the key
milestones to be achieved and the factors involved in the in-
clusion of ivermectin into the malaria toolbox.
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